Combinatorial prevention of HIV transmission in women: The case for a vaginal microbicide

Future Microbiology

Volumn 6, Issue 7, 2011, Pages 731-737

  Bélec, Laurent ^a,b   Jenabian, Mohammad Ali ^a,b   Charpentier, Charlotte ^a,b   Saïdi, Hela ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NONE   (France)

Author keywords

Africa; developing countries; HIV; HIV prevention; microbicide; pre exposure prophylaxis; preventive vaccine; sexual transmission; women

Indexed keywords

EMTRICITABINE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; PLACEBO; RECOMBINANT VACCINE; SMALL INTERFERING RNA; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CIRCUMCISION; CONSULTATION; DISEASE TRANSMISSION; DRUG RESISTANCE; FEMALE CIRCUMCISION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFORMED CONSENT; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SEXUAL TRANSMISSION; STANDARDIZATION; TREATMENT OUTCOME;

EID: 79961037339     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.64     Document Type: Article

References (40)

1. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. Joint United Nations Program on HIV/AIDS, Geneva, Switzerland (2010).
2. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin. Infect. Dis. 51, 725-731 (2010).
3. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 346, 530-536 (1995).
4. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 24, 621-635 (2010).
5. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2, E298 (2005).
6. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643-656 (2007). (Pubitemid 46281312)
7. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657-666 (2007).
8. Hallett TB, Alsallaq RA, Baeten JM et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sex. Transm. Infect. 87, 88-93 (2011).
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
11. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
12. Donnell D, Baeten JM, Kiarie J et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375, 2092-2098 (2010).
13. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 48-57 (2009).
14. Pilcher CD, Tien HC, Eron JJ Jr et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189, 1785-1792 (2004). (Pubitemid 38657214)
15. WHO. World Health Organization Recommendations. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2010 Version). WHO, Geneva, Switzerland (2010).
16. Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect. Dis. 10, 155-166 (2010).
17. Bélec L, Ghys PD, Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184, 1412-1422 (2001). (Pubitemid 33108855)
18. Shearer G, Clerici M. Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us? J. Infect. Dis. 202(Suppl. 3), S329-S332 (2010).
19. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269-280 (2011).
20. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 9, E875 (2007).
21. Vermund SH, Van Damme L. HIV prevention in women: next steps. Science 331, 284 (2011).
22. Saidi H, Jenabian A, Belec L. Early events in vaginal HIV transmission: implications in microbicide development. Future Virol. 4, 259-269 (2009).
23. Hilber AM, Chersich MF, van de Wijgert JH, Rees H, Temmerman M. Vaginal practices, microbicides and HIV: what do we need to know? Sex. Transm. Infect. 83, 505-508 (2007). (Pubitemid 350290967)
24. Hilber AM, Francis SC, Chersich M et al. Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS ONE 5, E9119 (2010).
25. Low N, Chersich MF, Schmidlin K et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 8, E1000416 (2011).
26. Doncel GF, Joseph T, Thurman AR. Role of semen in HIV-1 transmission: inhibitor or facilitator? Am. J. Reprod. Immunol. 65, 292-301 (2011).
27. Jenabian MA, Saïdi H, Charpentier C et al. Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Res. Ther. 7, 16 (2010).
28. Van de Perre P, Segondy M, Foulongne V et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect. Dis. 8, 490-497 (2008). (Pubitemid 352005823)
29. Jenabian MA, Saïdi H, Charpentier C et al. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J. Antimicrob. Chemother. 64, 1192-1195 (2009).
30. Keller MJ, Tuyama A, Carlucci MJ, Herold BC. Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother. 55, 420-423 (2005). (Pubitemid 40542578)
31. Galen BT, Martin AP, Hazrati E. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J. Infect. Dis. 195, 1332-1339 (2007). (Pubitemid 46649620)
32. Moench TR, Mumper RJ, Hoen TE, Sun M, Cone RA. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect. Dis. 10, 331 (2010).
33. Grant RM, Hamer D, Hope T et al. Whither or wither microbicides? Science 321(5888), 532-534 (2008).
34. Buckheit RW Jr, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 85, 142-158 (2010).
35. Palliser D, Chowdhury D, Wang QY et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439(7072), 89-94 (2006). (Pubitemid 43053634)
36. Wu Y, Navarro F, Lal A et al. Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 5, 84-94 (2009).
37. Wheeler LA, Trifonova R, Vrbanac V et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest. 121(6), 2401-2412 (2011).
38. Vallely A, Lees S, Shagi C et al. How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania. BMC Med. Ethics 11, 10 (2010).
39. Veldhuijzen N, Nyinawabega J, Umulisa M et al. Preparing for microbicide trials in Rwanda: focus group discussions with Rwandan women and men. Cult. Health Sex. 8, 395-406 (2006). (Pubitemid 44269683)
40. Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin. Infect. Dis. 50(Suppl. 3), S122-S129 (2010).